September 10, 2021

Nonalcoholic Steatohepatitis (NASH)

A Phase 2b, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Saroglitazar Magnesium in Subjects with Nonalcoholic Steatohepatitis and Fibrosis   Study […]
May 31, 2021

Ulcerative Colitis

Study title Phase 1, Open Label, Drug Interaction Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in […]
May 31, 2021

Ulcerative Colitis

Study title ECO-RESET: A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter Study to Assess Efficacy and Safety of SER-287 in Adults with Active Mild-to-Moderate Ulcerative […]
May 31, 2021

Ulcerative Colitis

Study title A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis (QUASAR) Disease or condition Ulcerative colitis Study type Interventional  (Clinical Trial) […]
May 31, 2021

Primary Sclerosing Cholangitis

Study title A Randomized, Double-blind, Dose-ranging, Placebo-controlled, Phase 2a Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Primary Sclerosing Cholangitis (PSC) and […]
May 31, 2021

Primary Sclerosing Cholangitis

Study title Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis (SHIP) Disease or condition Primary sclerosing cholangitis Study type Interventional  (Clinical Trial) Intervention/treatment Sulfasalazine or placebo Phase 2 Study […]
May 31, 2021

Primary Sclerosing Cholangitis

Note: this study is at multiple sites in North Carolina Study title Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Adults With Primary Sclerosing Cholangitis (PRIMIS) […]
May 31, 2021

Primary Biliary Cholangitis

Study title A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to evaluate efficacy and safety of Elafibranor 80 mg in Patients with Primary Biliary […]
May 31, 2021

Nonalcoholic Steatohepatitis (NASH)

Study title ARMOR: Phase 3/4 Double-Blind, Placebo-Controlled Clinical Study to Evaluate Aramchol in Subjects with Nonalcoholic Steatohepatitis (NASH) Disease or condition NAFLD/NASH with Fibrosis Study type […]
JOIN NOW